scholarly journals Implications of miRNA expression pattern in bovine oocytes and follicular fluids for developmental competence

2020 ◽  
Vol 145 ◽  
pp. 77-85 ◽  
Author(s):  
R. Pasquariello ◽  
E.F.M. Manzoni ◽  
N. Fiandanese ◽  
A. Viglino ◽  
P. Pocar ◽  
...  
2014 ◽  
Vol 20 (14) ◽  
pp. 1851-1859 ◽  
Author(s):  
M Muñoz-Culla ◽  
H Irizar ◽  
T Castillo-Triviño ◽  
M Sáenz-Cuesta ◽  
L Sepúlveda ◽  
...  

Background: Natalizumab has shown its efficacy in reducing multiple sclerosis (MS) relapses and progression of disability; however, it has been associated with an increased risk of developing progressive multifocal leukoencephalopathy (PML). The differential expression of microRNA (miRNA), the small non-coding RNAs that regulate gene expression, in natalizumab-treated patients has been reported and miRNA have also been described as good candidates for disease biomarkers. Objective: To characterize the effect of natalizumab therapy on the miRNA expression pattern and to search for miRNAs that can predict PML on an individual basis. Methods: The expression of 754 microRNAs was measured in blood samples from 19 relapsing–remitting MS patients at three time points during natalizumab therapy, using TaqMan OpenArray panels. Two patients included in this study developed PML after more than 2 years of therapy. Results: We found that the expression level of three miRNAs (let-7c, miR-125a-5p and miR-642) was affected after 6 months of therapy (t6). Furthermore, we observed a differential expression of another three miRNAs (miR-320, miR-320b and miR-629) between the PML and non-PML groups after 12 months of treatment (t12); and a positive correlation was found between therapy time and the expression of miR-320. Conclusions: Natalizumab modified the expression levels of three miRNAs after a 6-month treatment. We suggest miR-320, miR-320b and miR-629 as possible biomarkers for individual PML risk assessment.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1463-1463
Author(s):  
Su Ming Sun ◽  
Menno K Dijkstra ◽  
André C Bijkerk ◽  
Rik Brooijmans ◽  
Peter J Valk ◽  
...  

Abstract Abstract 1463 Poster Board I-486 Normal human myelopoiesis is a complex biological process, where the balance between cell proliferation, differentiation and apoptosis is tightly regulated by a transcriptional program that results in the production of appropriate numbers of circulating mature myeloid cells. MicroRNAs (miRNAs) are small non-coding RNAs of 18∼25 nt that can affect cellular protein levels. Several studies show specific miRNA expression patterns in different subtypes of myeloid malignancies, however only limited data is available on miRNA expression patterns during normal myeloid differentiation of primary human cells. We set out to characterize miRNA expression patterns in the different stages of granulocytic differentiation in two models. First myeloblast, promyelocytes, metamyelocytes and granulocytes from normal human bone marrow were cell-sorted with flow cytometry using the markers CD10, CD11, CD34, CD36, CD45 and CD117. Second, CD34+ cells from primary human fetal livers were differentiated in vitro towards neutrophils. MiRNA expression levels were determined at different time points (day 0, 3 and 10), representing different stages of granulocytic differentiation. MiRNA expression was measured using the qPCR platform, containing 365 miRNAs, from Applied Biosystems. To identify potential miRNA target genes, we performed mRNA expression profiling in the latter in vitro differentiation. The negative correlations between miRNA and mRNA expression were identified and integrated with a target prediction database (Targetscan). The miRNA profiling showed that approximately 70% of the 365 miRNAs analyzed, were expressed during granulocytic differentiation and that the miRNA expression pattern during this process change significantly in both models. Principal component analysis showed clear separation of the different subsets of granulopoiesis based on the miRNA expression. We determined the differentially expressed miRNAs between the various subsets using ANOVA with a P value <0.05, after correction for multiple testing. We found 24 miRNAs to be differentially upregulated in the both models. The top 5 upregulated miRNA, with the highest fold change in granulocytes as compared to myeloblasts, were miR-223, miR-145, miR-148, miR-24 and miR-23a. We identified 27 miRNAs that were downregulated, the top 5 were of miR-10a, miR-196a, miR-130a, miR-135a and miR-125b. Concomitant miRNA and mRNA expression analysis of the in vitro model with the Targetscan database, demonstrates a potential regulatory role for these miRNAs in various processes, such as cell proliferation, apoptosis and cell cycle regulation. For example, miR-130a, miR-20b and miR-191, miR-301 expression levels were negatively correlated with E2F2 and SOX4 respectively. Furthermore, MAPK1 levels correlated inversely with miR-17-5p, miR-130a, miR-181b, miR-181d and miR-20b. We observed potential regulation of BCL2L11 by miR-10a, miR-10b and CDK6 by miR-148a, miR-148b, miR-191 and miR-21, as well as CHEK1 by the miR-15a and miR-16, LATS2 by miR-142-3p and CCND3 by miR-133a. In addition we also identified myeloid specific genes to be potentially regulated by miRNAs such as CEBPA by miR-181b, KIT by miR-148a, miR-148b and miR-301 and RUNX3 by miR-301. This is the first comprehensive study of miRNA expression in normal human granulocytic differentiation. We show in two models that the miRNA expression pattern changes during granulocytic differentiation. miRNA-mRNA analyses suggest involvement of miRNAs in regulation of important cellular processes during granulocytic differentiation. Experimental validations of several candidate targets as well as functional studies are currently ongoing. Disclosures No relevant conflicts of interest to declare.


2009 ◽  
Vol 27 (6) ◽  
pp. 255-268 ◽  
Author(s):  
Emanuela Boštjančič ◽  
Nina Zidar ◽  
Damjan Glavač

MicroRNAs (miRNAs), small non-coding RNA molecules, are negative regulators of gene expression. Recent studies have indicated their role in various forms of cardiovascular disease. In spite of the number of miRNA microarray analyses performed, little is known about the genome-wide miRNA expression pattern in human myocardial infarction (MI). Using miRNA microarrays and bioinformatic analysis, miRNA expression was analyzed on human MI and foetal hearts compared to healthy adult hearts, to determine whether there is any similar expression pattern between MI and foetal hearts, and to identified miRNAs that have not previously been described as dysregulated in cardiovascular diseases. Of 719 miRNAs analyzed, ∼ 50% were expressed in human hearts, 77 miRNAs were absent from all tested tissues and 57 were confidently dysregulated in at least one tested group. Some expression patterns appeared to be similar in MI and foetal hearts. Bioinformatic analysis revealed 10 miRNAs as dysregulated in MI not yet related to cardiovascular disease, and 5 miRNAs previously described only in animal models of cardiovascular diseases. Finally, qRT-PCR analysis confirmed dysregulation of 7 miRNAs,miR-150, miR-186, miR-210, miR-451, and muscle-specific, miR-1 and miR-133a/b; all of these are believed to be involved in various physiological and pathological processes.


2013 ◽  
Author(s):  
Shiying Cui ◽  
Xinchen Zhang ◽  
Xiaotang Yu ◽  
Yanfang Ding ◽  
Jinyao Zhao ◽  
...  

2013 ◽  
Vol 218 (1) ◽  
pp. 35-47 ◽  
Author(s):  
Charlotte Benoit ◽  
Hassina Ould-Hamouda ◽  
Delphine Crepin ◽  
Arieh Gertler ◽  
Laurence Amar ◽  
...  

Perinatal leptin impairment has long-term consequences on energy homeostasis leading to body weight gain. The underlying mechanisms are still not clearly established. We aimed to analyze the long-term effects of early leptin blockade. In this study, newborn rats received daily injection of a pegylated rat leptin antagonist (pRLA) or saline from day 2 (d2) to d13 and then body weight gain, insulin/leptin sensitivity, and expression profile of microRNAs (miRNAs) at the hypothalamic level were determined at d28, d90, or d153 (following 1 month of high-fat diet (HFD) challenge). We show that pRLA treatment predisposes rats to overweight and promotes leptin/insulin resistance in both hypothalamus and liver at adulthood. pRLA treatment also modifies the hypothalamic miRNA expression profile at d28 leading to the upregulation of 34 miRNAs and the downregulation of four miRNAs. For quantitative RT-PCR confirmation, we show the upregulation of rno-miR-10a at d28 and rno-miR-200a, rno-miR-409-5p, and rno-miR-125a-3p following HFD challenge. Finally, pRLA treatment modifies the expression of genes involved in energy homeostasis control such as UCPs and AdipoRs. In pRLA rat muscle,Ucp2/3andAdipor1/r2are upregulated at d90. In liver, pRLA treatment upregulatesAdipor1/r2following HFD challenge. These genes are known to be involved in insulin resistance and type 2 diabetes. In conclusion, we demonstrate that the impairment of leptin action in early life promotes insulin/leptin resistance and modifies the hypothalamic miRNA expression pattern in adulthood, and finally, this study highlights the potential link between hypothalamic miRNA expression pattern and insulin/leptin responsiveness.


Sign in / Sign up

Export Citation Format

Share Document